- Home
- BODI vs ADAG Comparison
BODI vs ADAG Comparison
Compare BODI & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BODI | ADAG |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 84.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BODI | ADAG |
|---|---|---|
| Price | $11.21 | $1.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.00 | $8.00 |
| AVG Volume (30 Days) | ★ 104.0K | 80.1K |
| Earning Date | 11-10-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,565,000.00 | $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | N/A | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.38 | $1.30 |
| 52 Week High | $12.33 | $3.16 |
Technical Indicators
Market Signals| Indicator | BODI | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 48.06 |
| Support Level | $10.18 | $1.61 |
| Resistance Level | $12.33 | $1.92 |
| Average True Range (ATR) | 0.99 | 0.16 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 69.21 | 40.74 |
Price Performance
Historical ComparisonAbout BODI The Beachbody Company Inc.
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.